Premium
Adriamycin impairs phagocytic function and induces morphologic alterations in human neutrophils
Author(s) -
Vaudaux Pierre,
Kiefer Bertrand,
Forni Michel,
Joris Isabelle,
Majno Guido,
Waldvogel Francis A.
Publication year - 1984
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19840801)54:3<400::aid-cncr2820540306>3.0.co;2-c
Subject(s) - phagocytosis , anthracycline , doxorubicin , granulocyte , in vitro , neutrophile , vincristine , medicine , pharmacology , microbiology and biotechnology , chemistry , immunology , biology , biochemistry , chemotherapy , cyclophosphamide , cancer , breast cancer
Normal human polymorphonuclear leukocytes (PMNL) were preincubated in vitro with methotrexate, 5‐fluorouracil, vincristine, cisplatin, Adriamycin (doxorubicin), and daunomycin for 15 hours before being tested in a phagocytic–bactericidal assay. Anthracycline‐treated PMNL were defective in phagocytosis and killing of the bacteria, in contrast to the other chemotherapeutic agents which allowed the PMNL to remain functional. The defect of Adriamycin‐treated PMNL resulted from decreased ingestion: 3 μg/ml Adriamycin inhibited by 50% of the uptake of Oil Red‐O particles. In this assay, the proportion of noningesting PMNL increased from ≦20% with 0.62 μg/ml to ≧90% with 10 μg/ml Adriamycin. Electron microscopy revealed that Adriamycin‐inactivated PMNL had rounded up, were depleted in glycogen, and had undergone profound nuclear changes. RNA and protein synthesis in PMNL were also affected. Adriamycin, besides producing neutropenia, may decrease the phagocytic function of circulating PMNL.